JP2022549621A5 - - Google Patents

Info

Publication number
JP2022549621A5
JP2022549621A5 JP2022518230A JP2022518230A JP2022549621A5 JP 2022549621 A5 JP2022549621 A5 JP 2022549621A5 JP 2022518230 A JP2022518230 A JP 2022518230A JP 2022518230 A JP2022518230 A JP 2022518230A JP 2022549621 A5 JP2022549621 A5 JP 2022549621A5
Authority
JP
Japan
Prior art keywords
25hc3s
salt
composition according
separate doses
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022518230A
Other languages
English (en)
Japanese (ja)
Other versions
JP7830313B2 (ja
JP2022549621A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/053315 external-priority patent/WO2021067297A1/en
Publication of JP2022549621A publication Critical patent/JP2022549621A/ja
Publication of JP2022549621A5 publication Critical patent/JP2022549621A5/ja
Application granted granted Critical
Publication of JP7830313B2 publication Critical patent/JP7830313B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022518230A 2019-09-30 2020-09-29 アルコール性肝炎の処置 Active JP7830313B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962908465P 2019-09-30 2019-09-30
US62/908,465 2019-09-30
US201962933206P 2019-11-08 2019-11-08
US62/933,206 2019-11-08
US202063060564P 2020-08-03 2020-08-03
US63/060,564 2020-08-03
US202063081208P 2020-09-21 2020-09-21
US63/081,208 2020-09-21
PCT/US2020/053315 WO2021067297A1 (en) 2019-09-30 2020-09-29 Treatment of alcoholic hepatitis

Publications (3)

Publication Number Publication Date
JP2022549621A JP2022549621A (ja) 2022-11-28
JP2022549621A5 true JP2022549621A5 (https=) 2023-10-16
JP7830313B2 JP7830313B2 (ja) 2026-03-16

Family

ID=75336475

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022518230A Active JP7830313B2 (ja) 2019-09-30 2020-09-29 アルコール性肝炎の処置

Country Status (13)

Country Link
US (2) US20220378802A1 (https=)
EP (1) EP4037650A4 (https=)
JP (1) JP7830313B2 (https=)
KR (1) KR20220075329A (https=)
CN (2) CN119868374A (https=)
AU (1) AU2020357818A1 (https=)
BR (1) BR112022005039A2 (https=)
CA (1) CA3155422A1 (https=)
IL (1) IL291287A (https=)
MX (1) MX2022003778A (https=)
PH (1) PH12022550698A1 (https=)
TW (1) TW202128184A (https=)
WO (1) WO2021067297A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3494125B1 (en) 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
EP4359420A4 (en) * 2021-06-25 2025-07-16 Durect Corp 25-HYDROXY-CHOLEST-5-EN-3-SULFATE CHOLINE, PROCESSES FOR THEIR PREPARATION, AND THEIR USES
EP4611888A1 (en) * 2022-10-31 2025-09-10 Intercept Pharmaceuticals, Inc. Uses of farnesoid x receptor agonists
WO2025101669A1 (en) * 2023-11-07 2025-05-15 Durect Corporation Treatment of alcohol-associated hepatitis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) * 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
US20150072962A1 (en) * 2012-04-12 2015-03-12 Virgini Commonwealth University Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosis
HRP20220112T1 (hr) * 2013-12-24 2022-04-15 Virginia Commonwealth University Upotreba oksidacijskog sulfata kolesterola (ocs) za liječenje akutne insuficijencije jetre
EP3494125B1 (en) * 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
EP3493810A4 (en) * 2016-08-02 2020-04-08 Durect Corporation COMPOSITIONS WITH OXYGENOUS CHOLESTERINSULFATE AND AT LEAST POLYALKYLENE GLYCOL, CARBOXYMETHYLCELLULOSE OR POLYOXYL GLYCERIDE

Similar Documents

Publication Publication Date Title
JP2022549621A5 (https=)
JP2023002544A5 (https=)
JP2023179764A5 (https=)
JP2024015120A5 (https=)
JP2018514534A5 (https=)
JP2016204396A5 (https=)
JPH0222229A (ja) 神経細胞及び神経繊維の疾患もしくは傷害の治療に用いる組み合わせ調合剤
JP2023120246A5 (https=)
JP2025510295A5 (https=)
JP2022518944A5 (https=)
KR101174966B1 (ko) 철이 발병에 관여하는 간질환의 치료
TWI441639B (zh) 用於治療卵巢癌之包含紫杉醇之組合
JP2024531188A5 (https=)
JP2023500020A5 (https=)
JP2019532112A5 (ja) 結節性痒疹を治療するための抗掻痒剤
JP2022521173A5 (https=)
JP2024540439A5 (https=)
WO2023280238A1 (zh) 一种包含绿原酸的药物组合物在制备治疗早期阿尔茨海默病的药物中的用途
CN109172550B (zh) 一种复合麻醉药物
JP2024540044A5 (https=)
FI105075B (fi) Kombinaatioinjektiovalmisteen käyttö
JP2025511401A5 (https=)
US20190183959A1 (en) Compositions, kits and methods for treating type ii diabetes mellitus
JP2025511402A5 (https=)
JP2005529152A5 (https=)